Axa’s Ingevity NGVT Stock Holding History

Axa’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-69,135	Closed	-$2.98M	–	705
2025 Q2	$2.98M	Buy	69,135 +61,467	+802%	+$2.37M	0.01%	678
2025 Q1	$304K	Hold	7,668	–	–	﹤0.01%	981
2024 Q4	$312K	Hold	7,668	–	–	﹤0.01%	989
2024 Q3	$299K	Sell	7,668 -1,672	-18%	-$66.6K	﹤0.01%	1014
2024 Q2	$408K	Buy	+9,340	New	+$451K	﹤0.01%	970

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SCM

Simcoe Capital Management New York $576M AUM 36.22% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Axa's NGVT Position: Q3 2025 in Review

Axa sold out of Ingevity (NGVT) in Q3 2025, closing a stake of 69,135 shares — an estimated $2.98M sold.

Axa first reported a position in NGVT in Q2 2024 and held it in 5 quarters. The position peaked at $2.98M in Q2 2025. 298 funds tracked by Wall St. Rank hold NGVT as of Q3 2025.

Axa reported no remaining Ingevity position as of Q3 2025 after selling out during the quarter.
Axa sold 69,135 Ingevity shares in Q3 2025, an estimated $2.98M.
Axa first reported a position in Ingevity in Q2 2024 and held it in 5 quarters.
Axa's Ingevity position peaked at $2.98M in Q2 2025.
298 funds tracked by Wall St. Rank held Ingevity as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.